Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857697 | 0.82 | NPC1 (0.33) | NPC1MEN1KMT2A | |
| SCHEMBL4313975 | 0.78 | MEN1 (0.34) | NPC1MEN1KMT2A | |
| SCHEMBL22065533 | 0.78 | NPC1 (0.32) | NPC1MEN1KMT2A | |
| SCHEMBL1660320 | 0.78 | AAK1 (0.32) | NPC1MEN1KMT2A | |
| SCHEMBL1661171 | 0.78 | NPC1 (0.32) | NPC1MEN1KMT2A | |
| SCHEMBL10271145 | 0.75 | AAK1 (0.31) | NPC1 | |
| SCHEMBL1661227 | 0.73 | SMARCA2 (0.41) | NPC1MEN1KMT2A | |
| Isopropyl Alcohol SCHEMBL28207243 | 0.72 | NPC1 (0.35) | NPC1MEN1KMT2A | |
| SCHEMBL24386951 | 0.71 | NPC1 (0.31) | NPC1MEN1KMT2A | |
| SCHEMBL5407414 | 0.71 | HTR2C (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC | 2005-12-08 | — | — | US | claimed |
| EP-0871625-B1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RES ANDDEVELOPMENT COMP (IE) | 2003-12-17 | — | — | EP | claimed |
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | BUTTERS MICHAEL (GB) | 2003-09-25 | — | — | US | claimed |
| EP-0871625-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | claimed |
| WO-1997006160-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-02-20 | — | — | WO | claimed |
| US-7193083-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7193083-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7193083-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC | 2005-12-08 | — | — | US | disclosed |
| US-6946555-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC (US) | 2005-09-20 | — | — | US | disclosed |
| EP-0871625-B1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RES ANDDEVELOPMENT COMP (IE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | BUTTERS MICHAEL (GB) | 2003-09-25 | — | — | US | disclosed |
| US-6586594-B1 | Reacting 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl) ethanone and 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine in the presence of zinc, iodine, lewis acids, aprotic solvents and optionally lead to form sterospecific fungicides | PFIZER, INC. | 2003-07-01 | — | — | US | disclosed |
| EP-0871625-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997006160-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | IKZF2, SLC39A11, IKZF3 | NPC1 906/4885MEN1 592/4885KMT2A 941/4885 |
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | SLC39A11, IKZF2, IKZF3 | NPC1 1204/4885MEN1 311/4885KMT2A 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.